Menten AI
Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability.We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.
Hans Melo
Co-Founder and CEO
Chinmaya Rath
Member Board of Directors
Stephan Kudlacek
Associate Director Protein Design
Andrea McNeal
Head of Business Development
Simona (Yakobov) Shimonov
Alliances Manager
Patrick Finneran
Senior Scientist, Biophysics
Carlos Barreto
Scientist, Protein Design
Bruno Novo
Cloud | DevOps Engineer
Musa Özboyacı
Scientist
Elliott Dolan, PhD
Scientist, Protein Design
Frequently Asked Questions about Menten AI
Who is the CEO of Menten AI?▼
The current CEO of Menten AI is Hans Melo, serving as Co-Founder and CEO.
How many employees does Menten AI have?▼
Menten AI has approximately 2-10 employees. We have mapped 10 people in their organizational chart.
What industry is Menten AI in?▼
Menten AI operates in the Biotechnology Research industry and is headquartered in San Francisco, California, United States.
What is Menten AI's funding stage?▼
Menten AI is at the seed funding stage.
Who are the key executives at Menten AI?▼
Key executives at Menten AI include Hans Melo (Co-Founder and CEO), Chinmaya Rath (Member Board of Directors), Stephan Kudlacek (Associate Director Protein Design), Andrea McNeal (Head of Business Development).
Where is Menten AI headquartered?▼
Menten AI is headquartered in San Francisco, California, United States.
Data sourced from Crustdata | the API for B2B company & people data. Access org charts, headcount, funding, and growth metrics for 60M+ companies.